21 studies found for:    poly iclc | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Poly-ICLC in Treated HIV Infection
Condition: HIV-1 Infected Adults With Chronic HIV-1 Infection
Intervention: Drug: Poly-ICLC
2 Recruiting A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Condition: Brain Tumors
Intervention: Drug: Poly ICLC
3 Recruiting A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma
Conditions: Pancreatic Adenocarcinoma Non-resectable;   Poly ICLC;   Dendritic Cells
Interventions: Biological: Poly-ICLC;   Biological: dendritic cell
4 Recruiting Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma
Condition: Brain and Central Nervous System Tumours
Interventions: Biological: IMA 950 multipeptide based vaccine;   Biological: Poly ICLC;   Drug: Temozolomide;   Radiation: radiotherapy;   Other: Immunomonitoring
5 Recruiting DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Conditions: Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Primary Peritoneal Cavity Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Primary Peritoneal Cavity Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IC Primary Peritoneal Cavity Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Biological: DEC-205/NY-ESO-1 fusion protein CDX-1401;   Drug: poly ICLC;   Drug: IDO1 inhibitor INCB024360;   Other: pharmacological study;   Other: laboratory biomarker analysis
6 Recruiting In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
Condition: Low-Grade B-cell Lymphoma
Interventions: Drug: rhuFlt3L/CDX-301;   Drug: Poly-ICLC
7 Recruiting Safety and Immunogenicity Study of Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With Melanoma
Condition: Melanoma
Interventions: Biological: pBCAR3-phosphopeptide;   Biological: pIRS2-phosphopeptide;   Biological: 2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)
8 Recruiting Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer
Condition: Breast Cancer
Intervention: Biological: 9 Peptides from Her-2/neu, CEA, & CTA + poly-ICLC
9 Recruiting CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Carcinoma of Unknown Primary;   Metastatic Intraocular Melanoma;   Mucosal Melanoma;   Stage IIB Intraocular Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Biological: recombinant flt3 ligand;   Biological: DEC-205/NY-ESO-1 fusion protein CDX-1401;   Biological: neoantigen-based melanoma-poly-ICLC vaccine;   Other: laboratory biomarker analysis;   Other: pharmacological study
10 Not yet recruiting GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Condition: Glioblastoma
Interventions: Drug: APVAC1 vaccine plus Poly-ICLC;   Drug: APVAC2 vaccine plus Poly-ICLC
11 Recruiting Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
Condition: Cutaneous T-cell Lymphoma
Interventions: Drug: Romidepsin;   Drug: Poly ICLC;   Radiation: Focal lesional radiation
12 Recruiting DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts in Transformation;   Untreated Adult Acute Myeloid Leukemia
Interventions: Biological: DEC-205/NY-ESO-1 fusion protein CDX-1401;   Drug: poly ICLC;   Drug: decitabine;   Other: laboratory biomarker analysis
13 Unknown  A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas
Conditions: Newly Diagnosed Pediatric Pontine Glioma.;   Newly Diagnosed Pediatric High Grade Glioma.;   Recurrent Pediatric High Grade Glioma.;   Recurrent Pediatric Low Grade Glioma.
Interventions: Biological: HLA-A2 restricted synthetic glioma antigen peptides vaccine;   Drug: Poly ICLC;   Genetic: Reverse transcriptase-polymerase chain reaction;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
14 Recruiting Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
Conditions: Melanoma;   Metastatic Melanoma;   Mucosal Melanoma
Interventions: Biological: Peptide Vaccine (LPV7) + Tetanus peptide;   Other: PolyICLC;   Other: Resiquimod;   Other: IFA
15 Recruiting Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions: Biological: basiliximab;   Biological: WT1 126-134 peptide vaccine;   Drug: Montanide ISA 51 VG;   Drug: poly ICLC;   Other: laboratory biomarker analysis
16 Recruiting Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Biological: Vaccine + PolyICLC
17 Recruiting Dendritic Cell Vaccine for Patients With Brain Tumors
Conditions: Glioma;   Anaplastic Astrocytoma;   Anaplastic Astro-oligodendroglioma;   Glioblastoma
Interventions: Biological: autologous tumor lysate-pulsed DC vaccination;   Biological: Tumor lysate-pulsed DC vaccination+0.2% resiquimod;   Biological: Tumor-lysate pulsed DC vaccination +adjuvant polyICLC
18 Recruiting Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
Condition: Advanced Myeloma.
Interventions: Biological: Prevnar- Pneumococcal Conjugate Vaccine (PCV);   Other: Activated/costimulated autologous T-cell;   Drug: Lenalidomide;   Biological: MAGE-A3, Hiltonol® (Poly-ICLC)
19 Recruiting A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Condition: Melanoma
Interventions: Biological: Poly-ICLC;   Biological: Peptides
20 Recruiting NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
Condition: Unresectable or Metastatic Melanoma
Interventions: Biological: Ipilimumab;   Biological: NY-ESO-1 Protein Vaccine;   Biological: NY-ESO-1 OLP4 Vaccine

Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results
Indicates status has not been verified in more than two years